NACARDI Screening Tool Shows Promise for Identifying Opioid-Related Cardiac Arrests During Emergency Resuscitation

Could NACARDI Transform Resuscitation Outcomes?

Recent research has validated a promising clinical tool aimed at addressing the growing challenge of identifying opioid-associated out-of-hospital cardiac arrest (OA-OHCA) during resuscitation efforts. The NAloxone Cardiac ARrest Decision Instrument (NACARDI), a simple two-criteria screening tool, has demonstrated excellent performance in distinguishing occult opioid overdoses from other cardiac arrest etiologies in a Canadian population, potentially offering emergency medical services (EMS) providers a practical method for targeting life-saving interventions during critical moments of care. Over the past two decades, OA-OHCA cases have increased dramatically, now representing between 7-17% of all OHCA cases by 2023—approximately 10,500 to 25,000 cases annually in the United States alone. Despite this alarming trend, many cases remain unidentified during resuscitation efforts due to the absence of obvious signs of drug use, creating a significant barrier to appropriate treatment. The American Heart Association has specifically called for novel approaches to identifying these cases, recognizing that the distinct pathophysiology of opioid-induced cardiac arrest might benefit from targeted interventions such as naloxone administration.

This retrospective validation study examined 791 EMS-attended out-of-hospital cardiac arrests without an obvious cause in Ontario, Canada between 2020-2021. All cases were presumed to be non-drug-related by the treating EMS providers but were later investigated by a coroner. The study population was predominantly male (69.2%) with a median age of 61 years. Nearly half presented with asystole as their initial rhythm, while only 9.1% had shockable rhythms. Coroner adjudication ultimately identified 15.3% of these cases as opioid-associated, despite EMS providers not recognizing them as such during initial treatment. This finding underscores the challenge of identifying occult overdoses during resuscitation and highlights the potential value of a standardized screening approach. The NACARDI tool, which consists of just two criteria—patient age and unwitnessed cardiac arrest—was evaluated using two age thresholds: under 50 years (NACARDI-50) and under 60 years (NACARDI-60). Both versions demonstrated robust performance, with NACARDI-60 showing particularly strong results: 82.6% sensitivity, 77.1% specificity, 96.1% negative predictive value, and an impressive area under the ROC curve of 0.83. NACARDI-50 offered higher specificity (89.3%) but lower sensitivity (63.6%), suggesting that the choice between versions might depend on the specific clinical context and the relative importance of minimizing false positives versus false negatives.

What Factors Drove NACARDI's Exceptional Performance?

Interestingly, NACARDI performed better in this validation cohort than in its original derivation study conducted in San Francisco. This unusual outcome might be attributed to several factors, including a higher baseline prevalence of OA-OHCA in the validation cohort (15.3% versus 10.4%) and demographic differences, particularly the younger average age of OA-OHCA patients in the Canadian cohort (40.5 years versus 52.7 years). The researchers also note that the validation study occurred more recently (2020-2021 compared to 2011-2017), during a period of widespread increase in opioid overdoses, which may have influenced the patient spectrum in ways that enhanced the tool's performance. The robust performance was maintained even in a sensitivity analysis that excluded all cases with any evidence of drug use, including information available only to the coroner but not to EMS providers, suggesting the tool's utility in truly occult overdose scenarios. This finding is particularly important because it demonstrates NACARDI's ability to identify cases that would otherwise remain undetected during resuscitation efforts, potentially missing opportunities for targeted interventions like naloxone administration that could improve outcomes in this distinct subset of cardiac arrest patients.

How Does OA-OHCA Pathophysiology Inform Targeted Interventions?

The pathophysiology of OA-OHCA differs substantially from cardiac arrests due to primary cardiac etiologies. In opioid overdose, the sequence typically involves hypopnea and hypoxia, leading to bradycardia, reduced cardiac output, hypotension, and finally cardiac arrest. This distinct mechanism provides a rationale for why targeted interventions might be beneficial. Several retrospective studies have suggested that naloxone administration in drug-related OHCA is associated with improved clinical outcomes, although the evidence is not conclusive. NACARDI could serve as an important bridge between identifying high-risk patients and implementing appropriate interventions. By providing a standardized approach to risk stratification during resuscitation efforts, the tool could help EMS providers rapidly identify patients who might benefit from naloxone administration or other targeted treatments. Additionally, NACARDI could play a valuable role in future clinical trials by helping to define inclusion criteria for studies evaluating novel interventions for OA-OHCA. The simplicity of the tool—requiring only assessment of patient age and whether the arrest was witnessed—makes it particularly attractive for implementation in the high-stress, time-sensitive environment of cardiac arrest resuscitation, where complex algorithms might be impractical.

What Are the Study Limitations and Future Clinical Implications?

Despite these promising results, several limitations warrant consideration. The study's retrospective nature introduces potential selection bias, particularly regarding which cases were selected for coroner review. Local policies typically mandated examination for patients under 55 years or those with unexpected deaths, potentially overrepresenting younger patients and occult overdoses in the study cohort. This bias might artificially affect the tool's specificity by increasing the proportion of false positives relative to true negatives. Additionally, the validation was limited to patients who died during resuscitation efforts, excluding survivors who represent approximately 10% of OHCA cases. While this approach captures the majority of the target population, the tool's performance among survivors remains unknown. Geographic considerations also limit generalizability, as both the derivation and validation cohorts were drawn from large urban centers, potentially limiting applicability in rural settings where patterns of opioid use and EMS response capabilities might differ. These limitations highlight important areas for future research, including prospective validation studies across diverse geographic and demographic contexts, evaluation of NACARDI's performance among cardiac arrest survivors, and assessment of how implementation might affect clinical decision-making and patient outcomes.

The validation of NACARDI represents a significant step forward in addressing the growing challenge of opioid-associated cardiac arrests. By providing EMS providers with a simple, effective tool for identifying patients at high risk for occult opioid overdose, NACARDI could facilitate more targeted resuscitation efforts and potentially improve outcomes in this vulnerable population. The tool's strong performance in distinguishing OA-OHCA from other etiologies, particularly its high negative predictive value, suggests it could be valuable in clinical practice. As opioid overdoses continue to contribute significantly to cardiac arrest cases across North America, tools like NACARDI may become increasingly important components of emergency care protocols. Could the implementation of NACARDI in EMS protocols lead to increased appropriate use of naloxone during resuscitation efforts, and how might this affect survival rates in regions with high opioid use prevalence? What additional research is needed to determine whether early identification of OA-OHCA through NACARDI actually translates to improved patient outcomes through targeted interventions? How might the tool's performance vary across different demographic groups, particularly considering the known disparities in opioid overdose rates and EMS response? These questions highlight important directions for future research as the medical community continues to develop evidence-based approaches to combat the opioid epidemic and its deadly consequences.

Summary

Recent research has validated the NAloxone Cardiac ARrest Decision Instrument (NACARDI), a two-criteria screening tool designed to identify opioid-associated out-of-hospital cardiac arrest (OA-OHCA) during resuscitation efforts. The study examined 791 cardiac arrest cases in Ontario, Canada, where emergency medical services providers initially did not recognize opioid involvement, yet coroner investigations later confirmed 15.3% were opioid-related. NACARDI, which uses only patient age and whether the arrest was witnessed, demonstrated excellent performance with the under-60 version showing 82.6% sensitivity and 77.1% specificity. The tool performed even better than in its original San Francisco derivation study, possibly due to higher OA-OHCA prevalence and younger patient demographics in the Canadian cohort. This simple instrument addresses a critical clinical challenge as opioid-associated cardiac arrests now represent 7-17% of all out-of-hospital cardiac arrest cases, with many remaining undetected during resuscitation. The distinct pathophysiology of opioid-induced cardiac arrest, which progresses from respiratory depression to cardiac arrest rather than primary cardiac causes, provides rationale for targeted interventions like naloxone administration. NACARDI's simplicity makes it practical for high-stress resuscitation environments and could help standardize identification of patients who might benefit from targeted treatments. Study limitations include its retrospective design, focus only on patients who died during resuscitation, and validation in urban settings, highlighting needs for prospective studies across diverse geographic contexts and evaluation among cardiac arrest survivors to fully establish the tool's clinical utility and impact on patient outcomes.